// Mitigating the risks of long-term oncology eCOA clinical trials // What are the specific complexities of long oncology clinical trials? What are the relevant solutions to manage the risks regarding patient compliance, clinical project teams, and clinical sites? https://bit.ly/4fZWEbA #kayentis #eCOA #clinicaltrials #oncology
Kayentis
Fabrication de produits pharmaceutiques
Meylan, Auvergne-Rhone-Alpes 6 886 abonnés
Simplify your clinical trial experience
À propos
Kayentis, a global provider of eCOA (electronic Clinical Outcome Assessment) and Decentralized Clinical Trial solutions (DCTs), helps pharma, biotech and CROs bring simplicity, efficiency and quality to the collection of clinical trial data from both patients and sites. Since 2005, Kayentis has been active in clinical development, with a strong specialization in eCOA solutions for phases I-IV across a broad range of therapeutic areas. Over the years, it has developed a full range of services and has enlarged its portfolio beyond eCOA solutions to support the new normal of decentralized and hybrid trials. The company has conducted digital data collection for over 300 clinical trials in 90 countries (100,000 patients), employing 120 languages. It has offices in the US (Boston), France (Grenoble) and Japan (Tokyo), and currently employs 185 staff.
- Site web
-
https://kayentis.com/resources
Lien externe pour Kayentis
- Secteur
- Fabrication de produits pharmaceutiques
- Taille de l’entreprise
- 51-200 employés
- Siège social
- Meylan, Auvergne-Rhone-Alpes
- Type
- Société civile/Société commerciale/Autres types de sociétés
- Fondée en
- 2003
- Domaines
- eCOA solutions, Patient engagement, Electronic Clinical Outcome Assessments, Clinical Trials, ePRO, ClinRO, ObsRO, PerfO, eDiary, PRO, DCT solutions, BYOD et Televisit
Lieux
-
Principal
19 bis, Chemin du Vieux Chêne
38240 Meylan, Auvergne-Rhone-Alpes, FR
-
186 South St
Suite 600
02111 Boston, Massachusetts, US
Employés chez Kayentis
Nouvelles
-
// Understanding disease burden and the need for an individualized approach // 🙌 Having open discussions with patients has become necessary for the scientific community to deepen its understanding of the reality of patients’ day to day lives, and to be able to consider their various experiences throughout the steps of drug development. 🎗 At Kayentis we collaborate with several patient experts and associations. Last year, we invited Carine, Cecilia, and other fellow members from a cancer patient association which aims to enable women facing breast cancer to perform mountain activities as a reprieve from the heavy healthcare environment, and to find energy and self confidence that can often be lost following long periods of treatment or illness. Their testimonies highlight the value that listening to patients can bring to clinical research: https://bit.ly/3SYdVYy #kayentis #eCOA #clinicaltrials #oncology #EmpoweringPatientsVoices
Direct insights from cancer patients: How they help us understand disease burden and the need for an individualized approach - Kayentis
https://kayentis.com
-
// Addressing the specific complexities of oncology trials // What are the specific tools and keys to conduct successful eCOA trials in oncology? https://bit.ly/398PRhF #kayentis #clinicaltrials #eCOA #DCT #oncology
Addressing the specific complexities of oncology eCOA clinical trials - Kayentis
https://kayentis.com
-
// The relevance of ePROs in early phase clinical trials // Including the patient’s voice using electronic Patient Reported Outcomes in early phase studies can have a significant impact on the success of clinical development and market access: https://bit.ly/3OMLOd9 #kayentis #eCOA #clinicaltrials #EmpoweringPatientsVoices
The relevance of ePROs in early phase clinical trials - Kayentis
https://kayentis.com
-
// Rare disease clinical studies // 💡 Understanding the rare disease framework is essential to provide tailored solutions for study participants, thereby enhancing vital clinical research on rare diseases. ✅ At Kayentis, we have the full capability to run your rare disease clinical studies successfully. Get your demo: https://bit.ly/4eClNZ8 #kayentis #eCOA #clinicalstudies #raredisease
-
// Why you should join the #KayentisTeam // 🙌 At Kayentis, we value each individual and we form a community that goes beyond the sum of individuals. ✅ Our company’s growth is built on the competencies, experience, and values of its employees, including both hard and soft skills and irrespective of gender: https://bit.ly/4dbNLdc #kayentis #clinicalstudies #eCOA #employeesatisfaction #HR
Why you should join Kayentis - Kayentis
https://kayentis.com
-
// Dealing with multiple data sources in clinical trials // As the clinical trials industry embraces technology, the surge in data volume, variety, and sources brings about new challenges. How do we maintain data quality amidst this complexity? How do we ensure seamless integration and reconciliation of data from diverse systems like eCRF, eConsent, IRT/IxRS, and eCOA? Watch this insightful webcast where Sonja Banjac (PhD), Data Manager & Analyst at Kayentis, shares her expertise on data management strategies that support the integrity and efficiency of modern clinical trials. Discover tailored approaches to data integration and reconciliation that can streamline your processes and prevent data management from becoming a daunting task. #kayentis #eCOA #clinicaltrials #clinicaldatamanagement #IntegrationWhenItMakesSense
-
// Rare disease clinical trials // 💊 𝗢𝘃𝗲𝗿 𝟵𝟬% 𝗼𝗳 𝗿𝗮𝗿𝗲 𝗱𝗶𝘀𝗲𝗮𝘀𝗲𝘀 𝗵𝗮𝘃𝗲 𝗻𝗼 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁: understanding the rare disease framework is key to be able to offer study participants adapted solutions and as such, positively contribute to important and necessary clinical research conducted on rare diseases. 𝗞𝗮𝘆𝗲𝗻𝘁𝗶𝘀 𝗼𝗳𝗳𝗲𝗿𝘀 𝗮𝗻 𝗲𝘅𝘁𝗲𝗻𝘀𝗶𝘃𝗲 𝗲𝘅𝗽𝗲𝗿𝗶𝗲𝗻𝗰𝗲 𝗶𝗻 𝗿𝗮𝗿𝗲 𝗱𝗶𝘀𝗲𝗮𝘀𝗲 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝘁𝗿𝗶𝗮𝗹𝘀. To help make these trials successful: 💡 We have developed a deep knowledge of patients’ needs 👔 We have the ability to manage complexity 🧰 We propose options to manage compliance Download the case study: http://bit.ly/3ZrwJzR #kayentis #eCOA #clinicaltrials #raredisease
Rare Disease case study - Kayentis
https://kayentis.com
-
We're #hiring a new Clinical Operations Project Manager M/F - US in Boston, Massachusetts. Apply today or share this post with your network.
-
// Patients are ready for BYOD - are you? // BYOD undoubtedly improves user experience and benefits data quality. Need advice on your BYOD strategy? Ask our experts: https://bit.ly/4a5k4Ic #kayentis #eCOA #clinicaltrials #BYOD #patientcentricity
Pages similaires
Parcourir les offres d’emploi
Financement
Dernier round
Série inconnue2 384 547,00 $US